Developability considerations for bispecific and multispecific antibodies
Bispecific antibodies (bsAb) and multispecific antibodies (msAb) encompass a diverse variety of formats that can concurrently bind multiple epitopes, unlocking mechanisms to address previously difficult-to-treat or incurable diseases. Early assessment of candidate developability enables demotion of...
Saved in:
Main Authors: | Alaa Amash, Gesa Volkers, Patrick Farber, Daniel Griffin, K. Shawn Davison, Allison Goodman, Raffi Tonikian, Aaron Yamniuk, Bryan Barnhart, Tim Jacobs |
---|---|
Format: | Article |
Language: | English |
Published: |
Taylor & Francis Group
2024-12-01
|
Series: | mAbs |
Subjects: | |
Online Access: | https://www.tandfonline.com/doi/10.1080/19420862.2024.2394229 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Nonclinical immunogenicity risk assessment for knobs-into-holes bispecific IgG1 antibodies
by: Wen-Ting K. Tsai, et al.
Published: (2024-12-01) -
Prodrug-based bispecific antibodies for cancer therapy: advances and future directions
by: Zhijuan Ai, et al.
Published: (2025-01-01) -
Improving CD3 bispecific antibody therapy in solid tumors using combination strategies
by: Katy Lloyd, et al.
Published: (2025-02-01) -
A comparative study of the developability of full-length antibodies, fragments, and bispecific formats reveals higher stability risks for engineered constructs
by: Itzel Condado-Morales, et al.
Published: (2024-12-01) -
Applications and challenges in designing VHH-based bispecific antibodies: leveraging machine learning solutions
by: Michael Mullin, et al.
Published: (2024-12-01)